盐酸厄洛替尼一线治疗晚期非小细胞肺癌临床观察

Clinical study for previously untreated advanced non-small-cell lung cancer with erlotinib

目的分析盐酸厄洛替尼一线治疗33例晚期非小细胞肺癌的疗效、中位生存期、中位疾病进展时间以及对相关症状的控制,探索盐酸厄洛替尼作为晚期非小细胞肺癌一线治疗方案的可行性。方法33例经组织学或细胞学病理证实的ⅢB期或Ⅳ期非小细胞肺癌初治患者口服盐酸厄洛替尼150mg/d,直至患者死亡或肿瘤进展或发生不可耐受的毒副反应,服药前和服药后每月复查胸部CT进行肿瘤评估。结果客观缓解率为30.3%,疾病控制率为75.8%,性别、年龄、病理、体力状态评分等各亚组之间疗效差异均没有统计学意义(P>0.05),不吸烟患者的疗效优于吸烟患者(P<0.05)。中位疾病进展时间5.9个月,中位生存期9.3个月,最常见毒副反应为皮肤毒性,未观察到血液学毒性。结论盐酸厄洛替尼一线治疗晚期非小细胞肺癌,显示出良好的耐受性和有效性。

Objective By evaluating the efficacy,toxicity, median survival time and median time to progression of erlotinib in patients with previously untreated advanced NSCLC, to investigate the feasibility of erlotinib as first--line treatment to advanced NSCLC. Methods 33 cases with previously untreated NSCLC in stage ⅢB or Ⅳ confirmed by pathology or cytology were given Erlotinib 150mg orally once a day, until death or tumor progression or withdrawal by intolerable reaction. Responses and toxicities were evaluated in patients once a month. Results The response rate was 30.3%. The disease control rate was 75.8%. The time to progression was 5.9 months. The suvival time was 9.3 months. The skin toxicity is the most common and the blood toxicity is not observed. Conclusions Erlotinib is an effective first-line treatment for NSCLC,particularly for the elderly or the patients being not afford chemotherapy.